Zobrazeno 1 - 10
of 494
pro vyhledávání: '"Mikhail, Kosiborod"'
Autor:
Oliver Schnell, Katharine Barnard-Kelly, Tadej Battelino, Antonio Ceriello, Helena Elding Larsson, Beatriz Fernández-Fernández, Thomas Forst, Juan-Pablo Frias, James R. Gavin, Francesco Giorgino, Per-Henrik Groop, Hiddo J. L. Heerspink, Stephan Herzig, Michael Hummel, George Huntley, Mahmoud Ibrahim, Baruch Itzhak, Stephan Jacob, Linong Ji, Mikhail Kosiborod, Nebosja Lalic, Sofia Macieira, Rayaz A. Malik, Boris Mankovsky, Nikolaus Marx, Chantal Mathieu, Timo D. Müller, Kausik Ray, Helena W. Rodbard, Peter Rossing, Lars Rydén, Petra-Maria Schumm-Draeger, Peter Schwarz, Jan Škrha, Frank Snoek, Frank Tacke, Bruce Taylor, Britta Tendal Jeppesen, Solomon Tesfaye, Pinar Topsever, Tina Vilsbøll, Xuefeng Yu, Eberhard Standl
Publikováno v:
Cardiovascular Diabetology, Vol 23, Iss 1, Pp 1-17 (2024)
Abstract The 9th Cardiovascular Outcome Trial (CVOT) Summit: Congress on Cardiovascular, Kidney, and Metabolic Outcomes was held virtually on November 30-December 1, 2023. This reference congress served as a platform for in-depth discussions and exch
Externí odkaz:
https://doaj.org/article/167ffccba8024cf1934fce0e0b20bdf0
Autor:
Antonio Ceriello, Helena W. Rodbard, Tadej Battelino, Frank Brosius, Francesco Cosentino, Jennifer Green, Linong Ji, Monika Kellerer, Susan Koob, Mikhail Kosiborod, Nebojsa Lalic, Nikolaus Marx, T. Prashant Nedungadi, Christopher G. Parkin, Lars Rydén, Wayne Huey-Herng Sheu, Eberhard Standl, Per Olav Vandvik, Oliver Schnell, for the Taskforce of the Guideline Workshop
Publikováno v:
Cardiovascular Diabetology, Vol 22, Iss 1, Pp 1-5 (2023)
Abstract In recent years, several novel agents have become available to treat individuals with type 2 diabetes (T2D), such as sodium-glucose cotransporter-2 inhibitors (SGLT-2i), tirzepatide, which is a dual glucose-dependent insulinotropic polypepti
Externí odkaz:
https://doaj.org/article/27d5cfd5c6c14083a4d8c6448166a500
Autor:
Ali O. Malik, Hungta Chen, Fengming Tang, Paul S. Chan, Andrew Cooper, Marίlia B. Gomes, Vittal Hejjaji, Linong Ji, Kamlesh Khunti, Mikhail Kosiborod, Antonio Nicolucci, Poghni A. Peri-Okonny, Marina V. Shestakova, Jiten Vora, Hirotaka Watada, Suzanne V. Arnold
Publikováno v:
Indian Heart Journal, Vol 74, Iss 5, Pp 398-405 (2022)
Background: We sought to describe global patterns in achievement of risk factor control for primary prevention in patients with T2D and explore the association of country's GNI/capita with risk factor control. Methods: The DISCOVER study is a prospec
Externí odkaz:
https://doaj.org/article/0b861168d8c047968765dcefd3c338f7
Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER
Autor:
Suzanne V. Arnold, Fengming Tang, Andrew Cooper, Hungta Chen, Marilia B. Gomes, Wolfgang Rathmann, Iichiro Shimomura, Jiten Vora, Hirotaka Watada, Kamlesh Khunti, Mikhail Kosiborod
Publikováno v:
BMC Endocrine Disorders, Vol 22, Iss 1, Pp 1-7 (2022)
Abstract Background Despite strong evidence of benefit, uptake of newer glucose-lowering medications that reduce cardiovascular risk has been low. We sought to examine global trends and predictors of use of SGLT2i and GLP-1 RA in patients with type 2
Externí odkaz:
https://doaj.org/article/ec3b44102c7e4396b62acc311ae65d72
Autor:
Oliver Schnell, Tadej Battelino, Richard Bergenstal, Matthias Blüher, Michael Böhm, Frank Brosius, Richard D. Carr, Antonio Ceriello, Thomas Forst, Francesco Giorgino, Bruno Guerci, Hiddo J. L. Heerspink, Baruch Itzhak, Linong Ji, Mikhail Kosiborod, Nebojša Lalić, Michael Lehrke, Nikolaus Marx, Michael Nauck, Helena W. Rodbard, Giuseppe M. C. Rosano, Peter Rossing, Lars Rydén, Francesca Santilli, Petra-Maria Schumm-Draeger, Per Olav Vandvik, Tina Vilsbøll, Christoph Wanner, Carol Wysham, Eberhard Standl
Publikováno v:
Cardiovascular Diabetology, Vol 21, Iss 1, Pp 1-16 (2022)
Abstract The 7th Cardiovascular Outcome Trial (CVOT) Summit on Cardiovascular, Renal, and Glycemic Outcomes, was held virtually on November 18–19, 2021. Pursuing the tradition of the previous summits, this reference congress served as a platform fo
Externí odkaz:
https://doaj.org/article/00e116eff4ae44ebb18f8fbed0bc075e
Autor:
Meir Schechter, Cheli Melzer-Cohen, Aliza Rozenberg, Ilan Yanuv, Gabriel Chodick, Avraham Karasik, Mikhail Kosiborod, Ofri Mosenzon
Publikováno v:
Cardiovascular Diabetology, Vol 20, Iss 1, Pp 1-12 (2021)
Abstract Background Randomized controlled trials showed that sodium/glucose cotransporter-2 inhibitors (SGLT2i) protect the heart and kidney in an array of populations with type 2 diabetes (T2D) and increased cardiorenal risk. However, the extent of
Externí odkaz:
https://doaj.org/article/183d926e22824f2198fce8d59b95f101
Autor:
Jordi Real, Bogdan Vlacho, Emilio Ortega, Joan Antoni Vallés, Manel Mata-Cases, Esmeralda Castelblanco, Eric T. Wittbrodt, Peter Fenici, Mikhail Kosiborod, Dídac Mauricio, Josep Franch-Nadal
Publikováno v:
Cardiovascular Diabetology, Vol 20, Iss 1, Pp 1-11 (2021)
Abstract Background Evidence from prospective cardiovascular (CV) outcome trials in type 2 diabetes (T2DM) patients supports the use of sodium–glucose co-transporter-2 inhibitors (SGLT2i) to reduce the risk of CV events. In this study, we compared
Externí odkaz:
https://doaj.org/article/a7e7ad8919684a4ebb9ce7e799f82d86
Autor:
Kamlesh Khunti, Mikhail Kosiborod, Dae Jung Kim, Shun Kohsaka, Carolyn S. P. Lam, Su-Yen Goh, Chern-En Chiang, Jonathan E. Shaw, Matthew A. Cavender, Navdeep Tangri, Josep Franch-Nadal, Reinhard W. Holl, Marit E. Jørgensen, Anna Norhammar, Johan G. Eriksson, Francesco Zaccardi, Avraham Karasik, Dianna J. Magliano, Marcus Thuresson, Hungta Chen, Eric Wittbrodt, Johan Bodegård, Filip Surmont, Peter Fenici, the CVD-REAL Investigators and Study Group
Publikováno v:
Cardiovascular Diabetology, Vol 20, Iss 1, Pp 1-15 (2021)
Abstract Background Randomized, controlled cardiovascular outcome trials may not be fully representative of the management of patients with type 2 diabetes across different geographic regions. We conducted analyses of data from the multinational CVD-
Externí odkaz:
https://doaj.org/article/84b501fd6bee4a8d9bef97cb73d7d10c
Autor:
Suzanne V. Arnold, Kamlesh Khunti, Fabrice Bonnet, Bernard Charbonnel, Hungta Chen, Javier Cid‐Ruzafa, Andrew Cooper, Peter Fenici, Marilia B. Gomes, Niklas Hammar, Linong Ji, Gabriela Luporini‐Saraiva, Jesús Medina, Antonio Nicolucci, Larisa Ramirez, Marina V. Shestakova, Iichiro Shimomura, Filip Surmont, Fengming Tang, Jiten Vora, Hirotaka Watada, Mikhail Kosiborod, the DISCOVER investigators
Publikováno v:
ESC Heart Failure, Vol 8, Iss 2, Pp 1711-1716 (2021)
Abstract Aims Heart failure (HF) is increasingly recognized as a major cause of morbidity and mortality in patients with type 2 diabetes (T2D), but the global epidemiology and treatment of HF in T2D are not well defined. This study aimed to examine t
Externí odkaz:
https://doaj.org/article/6f0d5cf6e07a4fcc98c4a0e71fee4e3d
Autor:
Oliver Schnell, Xavier Cos, Francesco Cosentino, Thomas Forst, Francesco Giorgino, Hiddo J. L. Heersprink, Mikhail Kosiborod, Christoph Wanner, Eberhard Standl
Publikováno v:
Cardiovascular Diabetology, Vol 20, Iss 1, Pp 1-12 (2021)
Abstract The 6th Cardiovascular Outcome Trial (CVOT) Summit “Cardiovascular and Renal Outcomes 2020” was the first to be held virtually on October 29–30, 2020. As in previous years, this summit served as reference meeting for in-depth discussio
Externí odkaz:
https://doaj.org/article/ea242afe0c26401ca3536b3bbccb63fc